Rationale and Design of the IMPROVE Trial: A Multicenter, Randomized, Controlled, Open-label, Blinded-endpoint Trial Assessing the Efficacy of Remote Ischemic Conditioning in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting

AbstractIntroductionDespite the appearance of off-pump coronary artery bypass grafting (CABG), ischemia –reperfusion injury (IRI) in the perioperative period still arouses concerns of clinicians. Remote ischemic conditioning (RIC) is the process of repeated ischemia and reperfusion in the peripheral vessels, which is proven to reduce IRI in vital organs. However, the effect of RIC in patients underg oing off-pump CABG is still unclear.MethodsThis IMPROVE trial is a national, multicenter, randomized, controlled, open-label, blinded-endpoint clinical trial designed to assess whether RIC intervention can improve short-term prognosis of patients undergoing off-pump CABG. It plans to enroll 648 patients who will be randomly assigned into a RIC group or control group. Patients in the RIC group will receive four cycles of 5  min of pressurization (about 200 mmHg) and 5 min of rest in the 3 days before and 7 days after the surgery.Planned OutcomesThe primary outcome is the occurrence of major adverse cardiovascular and cerebrovascular events (MACCE) within the 3-month follow-up. MACCE is defined as all-cause death, myocardial infarction, stroke, and coronary revascularization surgery.Clinical Trial RegistrationNCT06141525 (ClinicalTrials.gov).
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research